Table 2.

The clinical and radiological parameters of the cohort.

Variables	LTP-negative (n = 83)	LTP-positive (n = 22)
Age (yr)∗	57.2 ± 8.8	58.4 ± 10.8
Sex
female	17 (20.48)	7 (31.82)
male	66 (79.52)	15 (68.18)
Location
left lobe	26 (31.33)	6 (27.27)
right lobe	54 (65.06)	15 (68.18)
bilobar	3 (3.61)	1 (4.55)
Hepatitis B virus
presence	68 (81.93)	15 (68.18)
absence	15 (18.07)	7 (31.82)
Tumor size
≤3 cm	65 (78.31)	13 (59.09)
>3 cm and ≤5 cm	18 (21.69)	9 (40.91)
Child-Pugh Class
A	26 (31.33)	9 (40.91)
B	57 (68.67)	13 (59.09)
Tumor margin
well-define	67 (80.72)	12 (54.55)
ill-define	16 (19.28)	10 (45.45)
Presence of liver cirrhosis	54 (65.06)	10 (45.45)
Pretreatment laboratory markers
Albumin > 1.0mg/dL	22 (26.51)	7 (31.82)
AFP > 100 ng/mL	5 (6.02)	11 (50)
ALT > 40 U/L	29 (34.94)	10 (45.45)
AST > 40 U/L	45 (54.22)	14 (63.64)
GGT > 50 U/L	57 (68.67)	15 (68.18)
Tumor number
1	75 (90.36)	14 (63.64)
2–3	8 (9.64)	8 (36.36)
Presence of rim enhancement
presence	17 (20.48)	13 (59.09)
absence	66 (79.52)	9 (40.91)
Presence of peritumoral enhancement
presence	11 (13.25)	4 (18.18)
absence	72 (86.75)	18 (81.82)
Signal in T2-weighted images
hyperintense	68 (81.93)	16 (72.73)
isointense	13 (15.66)	5 (22.73)
hypointense	2 (2.41)	1 (4.55)
Signal on arterial phase
hyperintense	72 (86.75)	17 (77.27)
isointense	10 (12.05)	4 (18.18)
hypointense	1 (1.20)	1 (4.55)
Signal on portal phase
hyperintense	3 (3.61)	2 (9.09)
isointense	35 (42.17)	9 (40.91)
hypointense	45 (54.22)	11 (50)
Signal on delay phase
hyperintense	2 (2.41)	1 (4.55)
isointense	32 (38.55)	8 (36.36)
hypointense	49 (59.04)	13 (59.09)
ADC (×10–3mm2/s)∗	1.09 ± 0.41	0.75 ± 0.26